Drugs / Cytosar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00850304 | Oct 2007 → Feb 2008 | acute myeloid leukemia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02462265 Background | Jan 2017 → Jun 2018 | acute myeloid leukemia, lymphoid leukemia | Oshadi Drug Administration | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytosar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02462265 ↗ |
| Route | Subcutaneous | “Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle” NCT00850304 ↗ |